First PDE-5 inhibitor recommended for use in paediatric population

Sildenafil is one of only two PDE5 inhibitors licensed for PAH.
Sildenafil is one of only two PDE5 inhibitors licensed for PAH.

The licence for Revatio (sildenafil) has been extended to include children over 1 year.

The phosphodiesterase type-5 inhibitor is approved for the treatment of pulmonary arterial hypertension (WHO class II and III) to improve exercise capacity.

Efficacy in paediatric patients has been shown in terms of improvement of exercise capacity or pulmonary haemodynamics, in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease

Before supplying Revatio for children under 20kg or patients unable to swallow tablets an oral suspension should be made using proprietary diluents (see SPC for full details).

However, Revatio IV remains unlicensed for use in patients under 18 years.

View Revatio drug record

Further Information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more